Amazing to me watching with an eerie feeling of deja vu. I was long in that large run of late '09 - I was long at .003 and .004 only because I had been given ActiPatch by a college buddy in Toronto for a sprained tennis ankle. Never heard of iHUB before that. Then the news came out 'speculating' about BIEL seeking FDA approval for OTC in the USA on top of its FDA approval already obtained for RecoveryRx for post-op use after eye surgery.
Everyone back in the day believed, with a billion or so shares BIEL would blow through half a buck on its run, as the only miniaturized safe and efficacious pain treatment without drugs and side-effects. No one could find any serious trial information to support an OTC submission and it turned out the guy hyping BIEL was Joe Noel, pure promoter, later SEC banned for life because of his actions involving another stock, he was not part of BIEL. People started to bail and I got out in numerous tranches between 9 and 10 cents, very few above 10. Noel was a contract promoter, nothing more, and was dumped - simple, he hyped it too much and way too early for the hit and run play. Many posters were there at the time and we were all smokin angry and some still. BIEL was way early, like 7+ years in its journey to OTC USA clearance. But credit to the company, they learned the hard way and persevered.
Years later, I started posting. I knew what ActiPatch had done for me and believed in the science, as others did. Bought a few shares, then bought a few more, then bought a lot more. BIEL management, to their credit never quit, nor did a large group of shareholders who had used the products. FDA actually had to do a complete 180 from denial to OTC USA clearance Feb 3 after starting to listen, learning the science, hiring staff who knew the science, reclassifying the science, renaming it from PEMF to SWT Short Wave Therapy and here we are folks, after FDA spent millions in man-hours - FDA OTC USA Cleared for ActiPatch for Plantar Fasciitis (foot tendon) and knee pain Feb 3 2017.
IMO, because FDA has now clearly stated unequivocally that ActiPatch is efficacious and safe for those 2 separate indications, common sense tells me there is no reason on earth ActiPatch should not be immediately cleared for all other indications - News Flash - it treats pain safely and efficaciously, period! ActiPatch for general tissue and joint pain and Allay for severe menstrual cramping and pain should be on the shelves now! No reason why not. Otherwise is absurd.
University of Oxford in the UK is finishing up a back trial and application has already been made to the NHS - National Health Service in the UK for universal healthcare coverage (free) for Recovery RX for all orthopedic surgery using B.Braun hardware and many want ActiPatch on the NHS tariff too for general pain. ActiPatch is in Boots pharmacies, the largest in the UK. Our FDA does not have to wait for the Oxford trial and data for back pain - it has already declared ActiPatch efficacious and safe on the foot and knee! Sorry for being repetitious, this really is a no-brainer. I would love to debate anyone mumbling, "well, yes, it is cleared for the foot and knee, but we need to be sure for other body parts . . . . " What!!!!
Only material differences between '09 and now? Ten times the shares because that's how this tiny company, with no money, financed its operation and pursuit of FDA clearance and we are now in the middle of a pain drug mis-use epidemic! But ass wise business people and investors know, it’s not about the number pof shares, it’s about market cap derived from projected sales and profit figures, nothing to do with share count. Those two thing tell me we should blow through 5 cents (1/10th of 50 cents in ’09) on the way up to BIEL announcing a License Agreement deal with a Big Pharma player with the infrastructure and deep pockets to roll out ActiPatch and Allay to every shelf in America and build a household must-have Brand.
Do the math, we thought it would blow through half a buck in '09, I think it's even better today, especially since the OTC clearance kind of snuck up on investors because after the first denial, no one took BIEL seriously at all, especially being on the PinkSheets.
Surprise, BIEL is coming like a tsunami, meanwhile it is now OTC in 50 other countries! Great story, great little American company, with patented IP and FDA OTC Clearance - deja vu
